ONCE - Spark Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
101.91
-3.16 (-3.01%)
At close: 4:00PM EDT

101.91 0.00 (0.00%)
After hours: 5:55PM EDT

Stock chart is not supported by your current browser
Previous Close105.07
Open103.27
Bid85.25 x 1800
Ask102.98 x 900
Day's Range101.25 - 104.08
52 Week Range34.53 - 114.20
Volume1,417,189
Avg. Volume787,490
Market Cap3.915B
Beta (3Y Monthly)1.78
PE Ratio (TTM)N/A
EPS (TTM)-2.31
Earnings DateAug 8, 2017 - Aug 14, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est105.03
Trade prices are not sourced from all markets
  • Markit7 days ago

    See what the IHS Markit Score report has to say about Spark Therapeutics Inc.

    Spark Therapeutics Inc NASDAQ/NGS:ONCEView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for ONCE with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on June 14. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding ONCE are favorable, with net inflows of $2.63 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Why This Gene Therapy Stock Looks Like A Sure Takeover Bet: Analyst
    Investor's Business Daily8 days ago

    Why This Gene Therapy Stock Looks Like A Sure Takeover Bet: Analyst

    Gene therapy player Uniqure could head to the auction block, an analyst said Monday as shares of the biotech company popped. He also said Roche's plan to buy Spark Therapeutics could falter.

  • Roche's $4.8 Billion Buyout Of Spark Delayed Amid Competitive Worries
    Investor's Business Daily15 days ago

    Roche's $4.8 Billion Buyout Of Spark Delayed Amid Competitive Worries

    Spark Therapeutics stock tumbled Monday after Swiss biopharma Roche delayed its $4.8 billion takeover of the biotech as regulators in the U.S. and Europe scrutinized the transaction.

  • Benzinga15 days ago

    Roche Extends Deadline For Spark Acquisition As US, UK Regulators Seek Additional Information

    The expiration date of Roche's offer has been extended from 5 p.m. Friday, June 14 to 5 p.m. July 31, which suggests Spark shareholders now have until July 31 to tender their shares. Roche has a lot riding on the Spark deal given the pharma giant's recent focus on gene therapies. Spark already has an approved gene therapy, Luxturna, for inherited retinal disease, and more investigational therapies in the pipeline for hemophilia A, hemophilia B, lysosomal storage disorders and neurodegenerative diseases.

  • TheStreet.com15 days ago

    Spark Therapeutics' Shares Fall on Roche Acquisition Delay

    may be delayed beyond the second quarter amid additional scrutiny from U.S. regulators. The companies said on Monday they had each received requests for additional information and documentary material from the U.S. Federal Trade Commission in connection with its review of the pending acquisition, prompting Roche to extend the tender offer period until next month. Because it is a "second request" from the FTC, part of the regulatory review process, the offer's waiting period has been extended from June 14 to July 31, the companies said in a statement on Monday.

  • $4.8 billion deal for gene therapy pioneer Spark Therapeutics delayed once more
    American City Business Journals15 days ago

    $4.8 billion deal for gene therapy pioneer Spark Therapeutics delayed once more

    With more questions coming from the FTC, Roche has extended the deadline of its tender offer for a fourth time.

  • Roche Receives FTC Request for Further Data on Spark Buyout
    Zacks15 days ago

    Roche Receives FTC Request for Further Data on Spark Buyout

    Roche (RHHBY) gets additional information request from FTC for the pending Spark acquisition.

  • Reuters15 days ago

    UPDATE 1-Roche's $4.3 bln Spark bid delayed again amid U.S., UK scrutiny

    Swiss drugmaker Roche's $4.3 billion takeover of U.S. gene therapy specialist Spark Therapeutics has been pushed back again, possibly beyond the first half, as regulators continue to scrutinize the deal for its effect on competition. Roche said on Monday that both companies received a request for more information from the U.S. Federal Trade Commission in connection with the FTC's review of the deal, sending Spark shares down nearly 15% at $93 in premarket trading on Monday. Roche also said that the UK Competition and Markets Authority (CMA) has opened an investigation.

  • Roche's $4.3 billion Spark bid delayed again amid U.S., UK scrutiny
    Reuters15 days ago

    Roche's $4.3 billion Spark bid delayed again amid U.S., UK scrutiny

    Swiss drugmaker Roche's $4.3 billion takeover of U.S. gene therapy specialist Spark Therapeutics has been pushed back again, possibly beyond the first half, as regulators continue to scrutinize the deal for its effect on competition. Roche said on Monday that both companies received a request for more information from the U.S. Federal Trade Commission in connection with the FTC's review of the deal, sending Spark shares down nearly 15% at $93 in premarket trading on Monday. Roche also said that the UK Competition and Markets Authority (CMA) has opened an investigation.

  • Hedge Funds Have Never Been This Bullish On Spark Therapeutics Inc (ONCE)
    Insider Monkey18 days ago

    Hedge Funds Have Never Been This Bullish On Spark Therapeutics Inc (ONCE)

    Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 12.1% in 2019 (through May 30th). Conversely, hedge […]

  • BIO 2019 panel: Gene therapy surging, but challenges remain
    American City Business Journals20 days ago

    BIO 2019 panel: Gene therapy surging, but challenges remain

    The heightened interest in, and steady growth of, gene therapies took center stage at BIO 2019 this week — but the optimism was tempered with discussions of challenges that still remain. While only a handful of gene therapies have received Food and Drug Administration approval, the federal agency has received 800 applications from companies wanting to begin testing experimental therapies, which involve introducing a healthy gene to replace or repair a missing or defective gene in patients with inherited diseases. “There a robust pipeline coming through,” said Peter Marks, a director with the FDA, during a gene therapy panel at the Biotechnology Innovation Organization annual international conference taking place in Philadelphia this week.

  • The 10 Best Stocks for 2019 — So Far
    InvestorPlace21 days ago

    The 10 Best Stocks for 2019 — So Far

    Despite the market's drubbing since late April, stocks are still up for the year. Some stocks, in fact, are still well up since the end of 2018. The best stocks for 2019 so far have been buoyed by strong backstories, impressive results or just an inordinate amount of rampant speculation.Regardless of the reason, that raw strength is worth a closer look. These big winners may be in the midst of unstoppable rallies, making these names some of the best stocks to buy for what looks like a rather rough summer. Or it's just as possible these big rallies have set up equally big selloffs, and profit-takers are ready plow in. * 6 Big Dividend Stocks to Buy as Yields Plunge While these may be the best stocks of 2019 so far in terms of performance, notice how few of them are mainstream or household names. Maybe being off the radar -- or working on an unbeatable business -- is the key to shrugging off marketwide lethargy.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Array Biopharma (ARRY)Source: Shutterstock YTD Gain: 97%Array Biopharma (NASDAQ:ARRY) has been the beneficiary of not one but two waves of great news this year, fueling two incredible surges. In January shares rallied on the heels of a successful phase 3 trial of one of its colon cancer therapies. Then, in May, ARRY stock popped again when the same combination therapy showed tremendous promise as a treatment for advanced melanoma.Though Array Biopharma is growing the top line at a strong double-digit rate, it's at a stage where the bigger the company gets, the more money it loses. It's going to need to lot more scale to get into the black, and that may not happen for a long while.Though analysts love ARRY for its story and potential, the current price is already very near the consensus target of $28.80. And the pros haven't seemed interested in upping that target. Sinclair Broadcast Group (SBGI)Source: Flash.pro via Flickr (modified)YTD Gain: 104%To be fair, shares of Sinclair Broadcast Group (NASDAQ:SBGI) started the new year out with something of an advantage for this list. SBGI has spent four straight years spinning its wheels, with SBGI stock making no net progress between the end of 2013 and late 2018. * 7 Stocks to Sell Impacted by the Mexican Tariffs The company may be one of the few traditional television outfits that's positioned to survive the cord-cutting phenomenon though. Sinclair is the company that bought most of the regional sports networks Walt Disney (NYSE:DIS) owned after it acquired Fox. It rallied leading into the news on speculation that it would happen, but continued to rally after the announcement on chatter that it was already thinking about distribution deals through non-traditional venues like Amazon.com (NASDAQ:AMZN). Iovance Biotherapeutics (IOVA)Source: (C)iStock.com/AlexRaths YTD Gain: 104%Despite being one of the best stocks of 2019 when looking at returns, biotech company Iovance Biotherapeutics (NASDAQ:IOVA) is pre-profit. In fact, it's pre-revenue. A handful of investors are enthused about its pipeline though, and particularly Lifileucel as a treatment for melanoma. It's in late-stage trials right now and looking very promising.At the same time, a recent update on its investigator-sponsored trial of LN-145 as a treatment of cervical cancer has also been well received.Of that testing, Emese Zsiros, M.D., Ph.D. and observer of the trial in question commented "The observation in the study of LN-145 that median DOR has not yet been reached at a median of 7.4 months following treatment provides evidence that this therapy could provide a clinically meaningful improvement over currently available options for patients with advanced cervical cancer."For the first time ever, Iovance Biotherapeutics is nearing a developmental endzone… a couple of endzones, actually. Guardant Health (GH)Source: Shutterstock YTD Gain: 108%Guardant Health (NASDAQ:GH) is not just one of this year's biggest winners and best stocks. It's also been one of the hottest IPOs of late. Only going public in early October, shares are already up an incredible 300%, and have gained more than 100% since the end of calendar 2018.Guardant Health is a developer of a handful of highly-focused oncology diagnostics tests. By digging deeper into genomic information, the company identifies which cancer treatment regimen would be most effective for a particular patient. Its technology has even proven useful for pharmaceutical developers looking to pinpoint genomic data that leads to better drug-testing outcomes. * 9 Trade War Stocks to Sell on U.S.-China Deal News The organization isn't profitable yet, but its strong revenue growth pace is leading to smaller and smaller losses that put Guardant Health on a path to profits in the foreseeable future. Mirati Therapeutics (MRTX)Source: Shutterstock YTD Gain: 110%Coming into the year, Mirati Therapeutics (NASDAQ:MRTX) was already on a bullish rampage more than doubling in 2018 thanks to progress with its pipeline.The lead drug is sitravatinib -- an immuno-oncology agent that, when used in conjunction with an anti-PD-1 checkpoint inhibitor drug Opdivo, shows promise as a second-line treatment for non-small-cell lung cancer. That phase 3 trial should be starting soon. The drug appeared to crash and burn given October's updated data, but another round of testing could still salvage that work.In the meantime, MRTX jumped more than 30% on Monday after rival drug company Amgen (NASDAQ:AMGN) offered an update on a drug similar to sitravatinib that validates sitravatinib itself.While encouraging, the total advance since mid-2017 looks and feels overextended. Though its been one of the best stocks of 2019 so far, I don't think the back half of the year holds much promise. Avalara (AVLR)Source: 401(k) 2012 via FlickrYTD Gain: 110%Avalara (NYSE:AVLR) is a software company with a good-sized suite of product, but its claim to fame and flagship is a sales tax-calculation tool that's become enormously important now that more and more states are enforcing the collection of sales tax on interstate e-commerce transactions.Sales growth hasn't been a problem. This year's projected top-line improvement of 28% extends a long-standing streak, and the pros are calling for comparable revenue growth this year. Where Avalara falls short is on the earnings front. Despite strong sales growth for years now, the company remains in the red… but not for much longer. If all goes as planned, this year's estimated loss of 18 cents per share following last year's loss of 67 cents should swing to a profit of eight cents per share. * 7 Stocks to Sell in June With operating earnings in sight, AVLR is up 110% so far this year, making it one of 2019's very best stocks to own. Snap (SNAP)Source: Shutterstock YTD Gain: 112%Shares of Snap (NYSE:SNAP) are up big time this year, but it's a gain with a major asterisk. That is, the triple-digit gain since late last year is a reclamation of the massive amount of ground SNAP stock lost in 2018. Even with that bullish move, SNAP stock is still only trading at about two-thirds of its early 2017 IPO price.Still, credit has to be given where it's due. The rebound rally was inspired by last quarter's smaller-than-expected loss and renewed progress in the number of daily users logging into the app.That said, more user growth could be in the cards now that the company recognizes simply have a communication platform isn't enough. It's starting to innovate in a big way, with the most recent idea being working directly with record labels to improve how music can be used in the app. Sea Limited (SE)Source: Shutterstock YTD Gain: 147%Sea Limited (NYSE:SE) offers several different types of digital entertainment to eastern Asian consumers -- particularly outside of China. But mobile and PC games along with eSports and e-commerce services are its core operations. Sea is best known, however, for its mobile wallet app called AirPay.It's been growing like crazy too. Though still booking losses (and likely to continue doing so for a few more years), sales are estimated to rise by almost 100% this year, and grow another 40% next year. The company has found its place, and stride. * 6 Big Dividend Stocks to Buy as Yields Plunge Nevertheless, this might be a rally to be wary of. While analysts will often up their consensus target as a stock rises, the current price near $28 is above a seemingly stagnant price target of just under $27. Spark Therapeutics (ONCE)Source: Shutterstock YTD Gain: 178%Take the huge 178% gain Spark Therapeutics (NASDAQ:ONCE) has dished out this year with a grain of salt. It all almost happened in one shot. In late February ONCE stock soared on the heels of news that drug company Roche (OTCMKTS:RHHBY) had made a very generous acquisition offer.The deal hasn't been consummated yet, and the FTC still needs to give it the green light. But, Roche says it expects the offer to be finalized and accepted before the end of the month.While it's unlikely the intended pairing will be derailed at this point, on the off chance it does, know that Roche's interest wasn't just Spark's Luxterna -- though it's the FDA's first-ever gene therapy treatment for a retinal disease that often leads to blindness. But ONCE's underlying gene therapy science has value well beyond that one application. Roku (ROKU)Source: Roku YTD Gain: 193%Finally, this year's biggest winner has been Roku (NASDAQ:ROKU), up almost 200% in just a little over five months.Like several other of the oversized gains we've seen since the end of 2018, Roku had the benefit of coming out of an oversized pullback during the last few months of last year. Nevertheless, the stock's earned every bit of its current price near $90.Roku, of course, is the name behind what's become the world's most popular streaming video receiver, dethroning several other (and bigger) consumer-tech companies that arguably should have been able to keep the young company at bay. * 7 Stocks to Sell Impacted by the Mexican Tariffs Whatever the case, this year's big move coincides with the company's discovery of several winning formulas and initiatives. Namely, Roku has figured out it can make even more money by selling ad space through its devices than just selling devices themselves. In that the latter fuels the former though, the pros are calling for an amazing 41% increase in this year's sales to be followed by 33% growth next year.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Stocks to Sell Impacted by the Mexican Tariffs * 6 Big Dividend Stocks to Buy as Yields Plunge * The 10 Biggest Announcements From Apple WWDC 2019 Compare Brokers The post The 10 Best Stocks for 2019 -- So Far appeared first on InvestorPlace.

  • American City Business Journals21 days ago

    BIO 2019: Philadelphia-area industry leaders put on a life sciences sales pitch for the region

    Videos, demonstrations and short speeches by industry leaders – including Spark's Jeff Marrazzo and Incyte's Herve Hoppenot – were used to entice leaders of biotech companies to consider the Philadelphia region as a replace to expand or relocate.

  • Spark CEO Marrazzo: Philadelphia will shine at BIO 2019
    American City Business Journals26 days ago

    Spark CEO Marrazzo: Philadelphia will shine at BIO 2019

    One of the more compelling stories at BIO 2019 will be the rise of Philadelphia as the hotbed for gene and cell therapy innovation and the potential for the city to capitalize on this moment

  • Options Traders Expect Huge Moves in Spark Therapeutics (ONCE) Stock
    Zacks28 days ago

    Options Traders Expect Huge Moves in Spark Therapeutics (ONCE) Stock

    Investors need to pay close attention to Spark Therapeutics (ONCE) stock based on the movements in the options market lately.

  • Roche Gets FDA Nod for Expansion of Cobas 6800/8800 Systems
    Zacks29 days ago

    Roche Gets FDA Nod for Expansion of Cobas 6800/8800 Systems

    Roche (RHHBY) gets FDA clearance for the expansion of its leading testing menu.

  • Sandell Asset Management’s Latest Moves
    Insider Monkeylast month

    Sandell Asset Management’s Latest Moves

    Sandell Asset Management is an alternative asset manager with a specialty in credit opportunities, global corporate merger arbitrage, and equity special situations. It was founded in 1998 by a renowned Swedish investor and billionaire, Tom Sandell. It provides offices in New York City and London. Tom Sandell cut his teeth at Bear Stearns, where he […]

  • Magnetar Capital’s Latest Moves
    Insider Monkeylast month

    Magnetar Capital’s Latest Moves

    Magnetar Capital is an Evanston, Illinois-based multi-strategy asset manager that was founded in 2005 by Alec Litowitz and Ross Laser, who previously worked at Citadel LLC and Glenwood Capital Partners, respectively. The fund was launched with $1.8 billion, which represented one of the biggest hedge fund initial capitals at the time. At the very beginning, […]

  • IQ merger arbitrage ETF bets on strong M&A space
    Yahoo Finance Video7 days ago

    IQ merger arbitrage ETF bets on strong M&A space

    The merger and acquisitions space is looking strong, topping $40 billion in deals for the first Monday in June, according to recent data. Sal Bruno, Chief Investment Officer at IndexIQ, joins Seana Smith on 'The Ticker' to discuss how this ETF can diversify investor portfolios.